Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Thromb Res. 2012 Jun 9;130(3):e163–e170. doi: 10.1016/j.thromres.2012.05.021

Figure 2. Ixolaris inhibits the establishment of B16F10 melanoma cells in vivo.

Figure 2

(A) B16F10 cells (2.5 × 105) were injected intravenously into C57BL/6 mice after previous injection of ixolaris (250 μg/kg) or PBS (see Materials and Methods). After 15 days, tumor nodules on harvested lungs were counted. Lines represent the mean of the number of pulmonary tumor nodules observed in the animals from each group. Representative lungs of each group are shown. (B) B16F10 cells (3.5 × 105) were injected subcutaneously into C57BL/6 mice. Daily treatment with ixolaris was initiated 3 days after tumor cell inoculation. Control animals were treated with an equivalent volume of PBS. After 18 days of tumor cell inoculation, the animals were sacrificed and the tumors were removed and weighed. Lines represent the mean of tumor weight in each group.